Skip to content

Inspection Record

Tropical Seas, Inc. — FDA 483 Findings

US FDAInspected 2018-05-30Published 2026-10-20 8 findingsEquipment and facilityDeviation, CAPA, and investigationProcess validationMaterial and supplier controlLaboratory and QC controlsTraining and personnel

Inspectors Saundrea A MunroeThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.

2Deviation, CAPA, and investigation

The written record did not include the reason an investigation was found not to be necessary when an investigation into unexplained discrepancies was not conducted.

3Process validation

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

4Material and supplier control

Each component is not added to the batch by one person and verified by a second person..

5Process validation

Written procedures are not followed that describe the in-process controls and examinations to be conducted on appropriate samples of in-process materials of each batch.

6Laboratory and QC controls

Laboratory records do not include a complete record of all data secured in the course of each test, including all graphs, charts and spectra from laboratory instrumentation, properly identified to show the specific component and drug product tested.

7Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Tropical Seas, Inc. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.